anonymous
Guest
anonymous
Guest
I guess ophthalmology sales aren’t going to catch up. That projection was way off before the recall.
Vabysmo sales are hot as hell.I guess ophthalmology sales aren’t going to catch up. That projection was way off before the recall.
Vabysmo sales are hot as hell.
Well the ecosystem model and inexperience in leadership accounts for the majority of the issues. Payer teams were dissolved a couple years ago so how did they expect this launch to go? FRM’s were being led by no one with experience. Pull through was a disaster.